DexCom enters $700M accelerated share repurchase agreement with JPMorgan

DEXCOM INC

Initial payment of $700M made to JPMorgan on August 1, 2022.
Initial delivery of ~3.0 million shares of common stock received on August 3, 2022.
Final settlement expected in Q3 2022; based on volume-weighted average price less discount.
Repurchase executed under existing $700M program with expiration by June 30, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.